Maravai Lifesciences Holdings (MRVI) Total Debt (2020 - 2026)

Maravai Lifesciences Holdings' Total Debt history runs 7 years deep, the most recent figure standing at $246.5 million for Q1 2026.

• On a quarterly basis, Total Debt fell 16.44% year-over-year to $246.5 million in Q1 2026; TTM through Mar 2026 was $246.5 million, a 16.44% decrease from a year earlier, with the FY2025 full-year figure at $291.8 million, down 3.19% from the prior year.
• Total Debt eased to $246.5 million in Q1 2026 per MRVI's latest filing, from $291.8 million in the prior quarter.
• Across five years, Total Debt topped out at $746.0 million in Q2 2022 and bottomed at $246.5 million in Q1 2026.
• The 5-year median for Total Debt is $523.3 million (2024), against an average of $476.9 million.
• Across the five-year window, Total Debt soared 40.07% in 2022 and tumbled 43.87% in 2025, its largest moves.
• Year by year, Total Debt stood at $527.4 million in 2022, then climbed by 0.41% to $529.6 million in 2023, then plunged by 43.09% to $301.4 million in 2024, then retreated by 3.19% to $291.8 million in 2025, then declined by 15.53% to $246.5 million in 2026.
• Per Business Quant, the three latest MRVI Total Debt figures stand at $246.5 million (Q1 2026), $291.8 million (Q4 2025), and $292.8 million (Q3 2025).